VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
Our Company
Vitalis is a privately-held specialty pharmaceutical company leveraging its proprietary VTS-Aspirin platform to overcome the limitations of existing drugs and enhance patient experience across a variety of therapeutic areas. We are initially targeting three highly promising therapeutic areas:
Our goal is to develop patient-centric therapies that improve disease treatment with fewer side effects, and that offer a higher quality of life.
Our purpose is rooted in the personal experience of one of Vitalis’ founders, and our culture was born out of the desire to serve patients and work on their behalf.
Executive Team
Vitalis brings together the brightest minds and experts from an array of cross-functional disciplines. As a team, Vitalis possesses the experience to discover, develop, and commercialize marketed therapies.
Dr. Joseph Habboushe
Inventor
Dr. Joseph Habboushe first developed an interest in the powerful and versatile effects of aspirin as a treatment while in medical school.
"My father needed to take niacin for his specific type of bad cholesterol but would often skip doses because of the flush it caused. I became interested in finding ways to use safe, well-understood, existing drugs to help solve some of the challenges that patients, like my father, faced."
Dr. Habboushe is a practicing emergency physician at a large hospital in New York City. He received his M.D. from Cornell University, where he is now Vice President of the Alumni Association Board of Directors, and his M.B.A. in Healthcare Finance from Columbia University, where he serves on the Healthcare & Pharmaceutical Program Board of Advisors.
Jason Simeral
Chief Operating Officer
Jason Simeral is an experienced entrepreneur and strategy consultant. He previously worked as a Senior Consultant for a global Strategy & Transformation consulting firm in NYC focused on pharmaceuticals and life sciences. He received his MBA from Columbia Business School.
Jon Levy
Head of Business Development
Jon Levy has been investing in privately held healthcare companies for 11 years. He has extensive experience in both private equity and venture capital investing, with specific sector expertise in pharmaceuticals and pharmaceutical services. Jon is a graduate of Yale University and received his MBA from Columbia Business School.
Board of Advisors
Jonathan Siegel
JBS Healthcare Ventures Kingdon Capital SAC Capital
Philippe Chambon, MD, PhD
Founder, New Leaf Venture Partners
Venture Partner, LBOFrance
CEO, Genelpis SAS
Aran Ron, MD
Former CMO, Oscar Insurance Bessemer Venture Partners Emblem Health
Vera Bittner, MD, MSPH
Aspirin Researcher
Former FDA Advisory Board
Professor, UAB Medical School
Gene Resnick, MD
Founder,
Millenix Oncology
Bunny Ellerin
Director, Healthcare and Pharmaceutical Management Program
Columbia Business School
Sahil Banka, MD
Cardiologist,
Drexel University
Michael Bell
Founder,
Mount Morris Advisors
Alexander Mauskop, MD
Founder, NY Headache Center Founder/Inventor, Migralex
Joan Spivak
Principal,
SpivakConsultingGroup
Utpal Patel
Owner & CEO
Sunrise Pharmaceuticals